Breast Cancer Liquid Biopsy Market Worth $1.7 Billion By 2030: IndustryARC

Breast Cancer Liquid Biopsy Market size is expected to reach $1.7 billion by 2030 after growing at a CAGR of 21.8% during the forecast period 2024-2030 according to the latest market research report published by IndustryARC. The growing demand of ,increasing preference of non- invasive procedures, advancements in technological capabilities and the increased breast cancer awareness programs for breast cancer are poised to propel the Breast Cancer Liquid Biopsy Market, finds IndustryARC in its recent report, titled “Breast Cancer Liquid Biopsy Market “- By Circulating Biomarkers (- Circulating Tumor Cells (CTCs) , Cell-free DNA (cfDNA), Cell- Free RNA (cfRNA), Circulating Tumor DNA (ctDNA), Circulating Tumor RNA (ctRNA), Extracellular Vesicles(EVs) and Other Biomakers), By Product (Consumables, Instruments and Services), By Application- Early Detection, Therapy Selection, Treatment Monitoring and Recurrence Monitoring, By End User (Research Institutes, Public Health Laboratories , Hospitals, Molecular Laboratories, Pathology Laboratories and Others), and By Geography Global Opportunity Analysis & Industry Forecast, 2024-2030.”

The escalating incidence of breast cancer, combined with the limitations and invasiveness of traditional diagnostic methods, has created a pressing need for innovative approaches as Breast Cancer Liquid Biopsy. This non-invasive technique offers the potential for earlier disease detection, enabling more proactive treatment strategies. By analyzing circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in blood samples, liquid biopsy provides valuable insights into tumor characteristics, facilitating personalized treatment plans and monitoring disease progression. As a result, there has been a substantial increase in demand for liquid biopsy services, underscoring its role as a transformative tool in breast cancer management. The World Health Organization's February 2023 report highlights that with over 2.3 million new cases annually, a leading cause of cancer death in many countries and in 95% of countries breast cancer is the first or second leading cause of female cancer deaths. To address this crisis, WHO launched a Global Breast Cancer Initiative Framework aimed at saving 2.5 million lives by 2040. The framework emphasizes early detection, timely diagnosis, and comprehensive management as crucial steps towards achieving this goal.

• Circulating Tumor Cells (CTCs) 

• Cell-free DNA (cfDNA)

• Cell- Free RNA (cfRNA)

• Circulating Tumor DNA (ctDNA)

• Circulating Tumor RNA (ctRNA)

• Extracellular Vesicles (EVs) 

• Other Biomakers

• Consumables

• Instruments 

• Services

• Research Institutes

• Public Health Laboratories

• Hospitals

• Molecular Laboratories

• Pathology Laboratories 

• Others.

• Early Detection

• Therapy Selection

• Treatment Monitoring 

• Recurrence Monitoring

• North America

• South America

• Europe

• Asia-Pacific

• Rest of the World

North America, spearheaded by the United States, maintains a dominant position in the breast cancer liquid biopsy market. As per a report by American Cancer Society, breast cancer is the second leading cause of cancer-related deaths and accounts for approximately one-third of all new female cancer diagnoses. While incidence rates have been slowly rising, the overall number of breast cancer cases and deaths in the U.S. for 2024 is estimated to be around 311,720 new cases of invasive breast cancer, 56,500 new cases of ductal carcinoma in situ (DCIS) and 42,250 deaths. The high volume of biopsy procedures underscores the critical role of advanced diagnostic techniques in the region and drives the robust growth of the cancer biopsy market in North America with well-established healthcare infrastructure, and substantial investments channelled into research and development within the life sciences sector. The region's favourable regulatory landscape for medical advancements, coupled with a strong emphasis on patient-centric care, has created a fertile ground for the growth and expansion of liquid biopsy services. 

The recurring demand for kits and reagents positions them as the primary revenue generators, underpinning the financial sustainability of the Breast Cancer liquid biopsy industry. These consumables, encompassing sample collection, extraction, assay, and ancillary reagents, are indispensable components of the liquid biopsy workflow. Their consumable nature, high volume usage, and continuous need for technological updates contribute to their dominance. Unlike capital-intensive instruments, kits and reagents are consumed for every test, ensuring a steady revenue stream. The diverse range of kits and reagents required for various liquid biopsy procedures further expands the market potential for these products. Labcorp, a leading global life sciences company introduced a new liquid biopsy test, Labcorp Plasma Focus, in May 2023. This innovative test empowers clinicians to select targeted therapies for patients with advanced or metastatic solid tumors.

Obtaining regulatory clearances for liquid biopsy tests is essential for market entry, widespread adoption, and patient access. These approvals validate the reliability of the technology, fostering investor confidence and driving industry growth. Navigating stringent regulatory landscapes, demonstrating clinical efficacy and safety, and compiling robust data packages are essential steps. A clear regulatory pathway is crucial for companies operating in this space. Overall, regulatory approvals are crucial for the successful commercialization and widespread adoption of liquid biopsy technology.

Guardant Health's Guardant360 CDx became the first FDA-approved blood-based liquid biopsy for diagnosing breast cancer and identifying patients eligible for elacestrant treatment in January 2024. This groundbreaking approval marks a significant milestone, offering new hope to patients with ESR1-mutated breast cancer who previously lacked targeted treatment options.

Patient-centric approach leverages personalized medicine by placing the individual patient at the core of the healthcare decision-making process. By placing the patient at the core of the diagnostic and treatment journey, liquid biopsy empowers individuals to make informed decisions about their healthcare. For example, LEO Pharma has established a strong reputation for its patient-centric approach to drug development and delivery. Through clear communication, shared decision-making, and access to comprehensive information, patients can actively participate in their care plans. The integration of liquid biopsy with personalized medicine specifically with precision oncology has enables the tailoring of treatment strategies based on individual tumor characteristics, leading to improved outcomes and an enhanced patient experience. It helps to look for variations in your DNA that might increase your risk of breast cancer and other types of cancer and helps understand how your body is likely to respond to a medicine by testing your DNA. 

By developing affordable and accessible medical technologies, establishing local manufacturing facilities, and fostering public-private partnerships, these companies contribute significantly to improving healthcare access and quality. This strategic approach not only benefits the local population but also creates new market opportunities for manufacturers. Prominent manufacturers are contributing significantly by providing advanced medical equipment, diagnostic tools, digital health solutions that enhance patient care, improve efficiency, and drive innovation. Their contributions are pivotal in advancing the overall accessibility of healthcare services and shaping the healthcare infrastructure landscape. For example, Medtronic focuses on medical devices for chronic diseases, including cardiac, respiratory, and diabetes management. Also, GE Healthcare offers a wide range of medical imaging and diagnostic equipment, contributing to improved disease detection and diagnosis.

Precision medicine is a pivotal force driving the expansion of the liquid biopsy market. By emphasizing the identification and targeting of unique molecular characteristics within tumors, precision medicine has created a significant demand for non-invasive diagnostic tools capable of capturing real-time insights into tumor biology. Liquid biopsy, with its ability to analyze circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), has emerged as an indispensable tool for enabling personalized treatment strategies, monitoring disease progression, and detecting minimal residual disease. In the face of traditional treatments that often come with severe side effects, precision medicine offers a beacon of hope by tailoring solutions to each individual's genetic makeup. As per the Indian Precision Medicine, in a survey conducted in 2023, more than half of life sciences investors were interested in opportunities in precision medicine along with AI and cell and gene therapy. And a plethora of big pharma companies are building up their precision medicine expertise, including Novartis, Pfizer, Roche, Johnson & Johnson, and more. This alignment between precision oncology and liquid biopsy is accelerating the development and adoption of this innovative technology, ultimately improving patient outcomes

The integration of liquid biopsy with artificial intelligence (AI) is accelerating its path to becoming a standard-of-care option in breast cancer management. AI's ability to analyze complex data sets rapidly and accurately is a game-changer for liquid biopsy. By processing vast amounts of information from circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), AI algorithms can identify patterns and biomarkers that may be imperceptible to human analysts. This leads to improved sensitivity, specificity, and predictive power of liquid biopsy tests. Furthermore, AI can optimize the liquid biopsy workflow, from sample preparation to data interpretation. Automation of routine tasks and the development of intelligent decision support systems can enhance efficiency and reduce turnaround times. The incorporation of artificial intelligence further elevates Exai Bio’s liquid biopsy platform by enabling advanced data analysis and pattern recognition. Machine learning algorithms can discern intricate molecular signatures associated with early-stage breast cancer, distinguishing them from benign variations. As the technology matures and clinical evidence grows, liquid biopsy is poised to become a standard-of-care tool for early detection, monitoring, and treatment selection in breast cancer. In March 2024, Trastuzumab deruxtecan (T-DXd), a major Standard of Care Regimens emerged as the preferred second-line treatment option for HER2+ metastatic breast cancer. While trastuzumab emtansine (T-DM1) remains a viable choice, T-DXd has demonstrated superior efficacy and is often the initial treatment of choice due to its improved progression-free survival and overall survival rates. However, treatment decisions should be individualized based on patient factors, disease characteristics, and potential side effects.

• Breast Cancer Liquid Biopsy Market size and Forecast 

• Breast Cancer Liquid Biopsy Market Trends

• Breast Cancer Liquid Biopsy Market analysis by Product

• CAGR of the market during the forecast period 2024-2030

• Value Chain analysis of key stake holders

• Detailed analysis of market drivers and opportunities during the forecast period

• Breast Cancer Liquid Biopsy Market size estimation and forecast

• Analysis and predictions on end user behavior and upcoming trends 

• Competitive landscape and Vendor market analysis including offerings, developments, and financials

• Comprehensive analysis of challenges and constraints in the Breast Cancer Liquid Biopsy Market

• The global focus on the pandemic led to disruptions in healthcare systems, including delayed cancer screenings and a shift in resource allocation. Consequently, the diagnosis and management of breast cancer, including the adoption of liquid biopsy, were affected. While the pandemic presented challenges, it also underscored the potential of liquid biopsy as a less invasive and safer diagnostic tool. The increased awareness of early disease detection and the accelerated pace of research in diagnostics contributed to a growing interest in liquid biopsy technologies

• The Russia-Ukraine conflict has indirectly impacted the breast cancer liquid biopsy market. Supply chain disruptions, economic instability, and a shift in global focus have created challenges for the industry. The availability of essential components, research funding, and talent acquisition have been affected, potentially slowing down advancements in liquid biopsy technology. However, the overall trend towards precision medicine and early cancer detection is likely to sustain growth in the market.

The companies profiled in the Breast Cancer Liquid Biopsy Market include:

Breast Biopsy Devices Market– Breast Biopsy Devices Market Size is projected to reach $3.4 Billion by 2030, after growing at a CAGR of 5.1% during the forecast period 2024-2030. Advancements in medical technology, rising incidence of breast cancer, and increasing awareness about early detection are driving the market growth.

Cancer Testing Screening Market – Cancer Testing Screening Market size is projected to reach $220.66 billion by 2027 and is expected to grow at a CAGR of 6.4% during the forecast period 2022-2027, owing to its usage for aid in the early detection of cancer before symptoms occur, particularly in countries with the highest cancer rates.

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.

Mr. Venkat Reddy

IndustryARC

Email: [email protected]

USA:(+1) 518-282-4727

Web: https://www.industryarc.com